158 related articles for article (PubMed ID: 8239529)
1. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
2. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II).
Esposito M; Viale M; Vannozzi MO; Zicca A; Cadoni A; Merlo F; Gogioso L
Toxicol Appl Pharmacol; 1996 Oct; 140(2):370-7. PubMed ID: 8887454
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A
Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476
[TBL] [Abstract][Full Text] [Related]
4. Improved therapeutic index of cisplatin by procaine hydrochloride.
Esposito M; Fulco RA; Collecchi P; Zicca A; Cadoni A; Merlo F; Rosso R; Sobrero A
J Natl Cancer Inst; 1990 Apr; 82(8):677-84. PubMed ID: 2319610
[TBL] [Abstract][Full Text] [Related]
5. Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia.
Fulco RA; Vannozzi M; Collecchi P; Merlo F; Parodi B; Civalleri D; Esposito M
Anticancer Res; 1990; 10(6):1603-10. PubMed ID: 2285232
[TBL] [Abstract][Full Text] [Related]
6. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
[TBL] [Abstract][Full Text] [Related]
8. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
10. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
11. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
12. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent influence of procaine hydrochloride on cisplatin antitumor activity in P388 tumor bearing mice.
Viale M; Vánnozzi MO; Mandys V; Esposito M
Anticancer Res; 2001; 21(1A):485-7. PubMed ID: 11299784
[TBL] [Abstract][Full Text] [Related]
14. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.
Naganuma A; Satoh M; Imura N
Cancer Res; 1987 Feb; 47(4):983-7. PubMed ID: 3802104
[TBL] [Abstract][Full Text] [Related]
15. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of DNA cross-linking in normal and neoplastic mouse tissues following treatment with cis-diamminedichloroplatinum(II) in vivo.
Murray D; Jenkins WT; Meyn RE
Cancer Res; 1985 Dec; 45(12 Pt 1):6446-52. PubMed ID: 4063992
[TBL] [Abstract][Full Text] [Related]
18. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
Terheggen PM; Floot BG; Scherer E; Begg AC; Fichtinger-Schepman AM; den Engelse L
Cancer Res; 1987 Dec; 47(24 Pt 1):6719-25. PubMed ID: 3315190
[TBL] [Abstract][Full Text] [Related]
20. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]